High CYP2C19 phenotypic variability in gastrointestinal cancer patients.

about

Indirect regulation of CYP2C19 gene expression via DNA methylation.Pharmacogenetics and precision medicine: Is inflammation a covert threat to effective genotype-based therapy?

P2860

Q38608601-4ECB58AD-CDEA-44BC-A6E0-E73CD96E4E0D Q42345777-CE806706-253A-4EB5-A876-95195BAC7ED7

P2860

High CYP2C19 phenotypic variability in gastrointestinal cancer patients.

Item

http://www.wikidata.org/entity/Q50271114

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

High CYP2C19 phenotypic variability in gastrointestinal cancer patients.

@en

High CYP2C19 phenotypic variability in gastrointestinal cancer patients.

@nl

type

Item

label

High CYP2C19 phenotypic variability in gastrointestinal cancer patients.

@en

High CYP2C19 phenotypic variability in gastrointestinal cancer patients.

@nl

prefLabel

High CYP2C19 phenotypic variability in gastrointestinal cancer patients.

@en

High CYP2C19 phenotypic variability in gastrointestinal cancer patients.

@nl

P1476

High CYP2C19 phenotypic variability in gastrointestinal cancer patients.

@en

P2093

G Laking

http://www.w3.org/2001/XMLSchema#string

K Sharples

http://www.w3.org/2001/XMLSchema#string

M P Findlay

http://www.w3.org/2001/XMLSchema#string

W-Y Lo

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response.

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

Malnutrition affects quality of life in gastroenterology patients

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.

Molecular basis of ethnic differences in drug disposition and response.

The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.

Addressing phenoconversion: the Achilles' heel of personalized medicine.

P2888

s00280-015-2923-4

P304

195-204

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-015-2923-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nuala A Helsby

Kathryn Elisa Burns

P577

2015-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26614509

http://www.w3.org/2001/XMLSchema#string

High CYP2C19 phenotypic variability in gastrointestinal cancer patients.

about

P2860

P2860

High CYP2C19 phenotypic variability in gastrointestinal cancer patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698